- Home
- VIVS vs XBIO Comparison
VIVS vs XBIO Comparison
Compare VIVS & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VIVS | XBIO |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | 13 | 2 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 5.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VIVS | XBIO |
|---|---|---|
| Price | $2.16 | $2.55 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 19.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.38 | $1.99 |
| Revenue Next Year | $15.42 | $20.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $1.90 |
| 52 Week High | $5.30 | $13.93 |
Technical Indicators
Market Signals| Indicator | VIVS | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 60.61 |
| Support Level | $2.08 | $2.47 |
| Resistance Level | $2.45 | $2.76 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 74.51 | 90.57 |
Price Performance
Historical ComparisonAbout VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.